Threshold to get $30M from Merck KGaA for pancreatic cancer drug trial

01/28/2013 | American City Business Journals

Merck KGaA will pay Threshold Pharmaceuticals a $30 million milestone fee for initiating a Phase III trial of investigational treatment TH-302 in combination with gemcitabine in patients with previously untreated metastatic pancreatic cancer. The trial will involve 660 patients and the main endpoint will be overall survival. TH-302 is also in a late-stage trial against soft tissue sarcoma.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
PRINCIPAL ENGINEER - R&D - 14000009CP
Abbott
Chicago, IL
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK